Pharmaceutical companies continue to plan for the UK’s exit from the EU. As they do, the terms on which the UK will leave - and the terms of the future relationship – remain uncertain.
Last week, the EMA announced it has completed the reallocation of the medicines for which the UK's national regulator - the MHRA - is currently rapporteur or co-rapporteur appointed by the scientific committees to coordinate the evaluation of a medicine.
Responding to a new House of Commons Health and Social Care Select Committee report ‘Brexit – Medicines, Medical Devices and Substances of Human Origin’, the trade associations representing the UK's pharmaceutical and biotech industries have issued a joint response backing the Committee's...
Making sure patients continue to get the medicines they need is of upmost importance as we negotiate the UK’s withdrawal from the EU.
As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.
The ABPI has responded to the Prime Minister's ‘Road to Brexit’ speech today at Mansion House.
The Association of the British Pharmaceutical Industry (ABPI) - representing leading global pharmaceutical businesses in the UK - have welcomed the EU Council's agreement to progress Brexit negotiations to the next phase and the EU Council's approval of a transition period.